Key result
Experimental and clinical evidence suggests that glycosaminoglycans may favorably affect primary and secondary renal diseases, highlighting the need for prospective randomized controlled trials.
Why the study?
Do glycosaminoglycans improve outcomes in patients with non-diabetic chronic glomerular diseases?
Population
Patients with primary and secondary chronic glomerular diseases (non-diabetic renal conditions)
Design
Review
Authors
Loading...
Evidence supports potential benefit in non-diabetic glomerular diseases; leaves open clinical efficacy pending RCTs.
Do glycosaminoglycans improve outcomes in patients with non-diabetic chronic glomerular diseases?
This review highlights the potential therapeutic role of glycosaminoglycans in non-diabetic glomerulonephritis and calls for large randomized controlled trials to establish clinical efficacy.
Gambaro et al. (2010) conducted a review in Primary and secondary chronic glomerular diseases. Glycosaminoglycans (GAGs) was evaluated. Experimental and clinical evidence suggests that glycosaminoglycans may favorably affect primary and secondary renal diseases, highlighting the need for prospective randomized controlled trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: